Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048659 · ClinicalTrials.gov registry record · Phase 2
YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
NCT00048659: Clinical Trial Phase 2 study, sponsored by Astellas Pharma.
NCT00048659 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048659, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
Interventions
- DRUG YM598
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
Why NCT00048659 stopped before completion
NCT00048659 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which YM598 is the first listed.
NCT00048659 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00048659 about?
NCT00048659 is a clinical study titled "YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy". The purpose of this study is to determine if patients who take YM598 in addition to mitoxantrone and prednisone (standard therapy) experience improvement in the pain associated with prostate cancer metastases in the bone.
What is the current status of trial NCT00048659?
This trial is currently terminated. It is a Phase 2 study. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00048659?
The interventions under investigation include: YM598 (DRUG).
Who is sponsoring clinical trial NCT00048659?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.